Suppr超能文献

针对感染性人乳头瘤病毒(HPV)颗粒衣壳上L1表位的单克隆抗体、Fab片段和单链抗体(scFv)的结合及中和效率。

Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.

作者信息

Culp Timothy D, Spatz Christin M, Reed Cynthia A, Christensen Neil D

机构信息

Gittlen Cancer Research Foundation, Pennsylvania State University, Hershey, PA 17033, USA.

出版信息

Virology. 2007 May 10;361(2):435-46. doi: 10.1016/j.virol.2006.12.002. Epub 2007 Jan 12.

Abstract

We compared the neutralization abilities of individual monoclonal antibodies (MAb) of two large panels reactive with L1 epitopes of HPV-11 or HPV-16. Binding titers were compared using both L1-only VLPs and L1/L2 pseudovirions. While the VLPs were antigenically similar to the pseudovirions, clear differences in the surface exposure of some epitopes were evident with the HPV-16 particles. To determine whether all antibody binding events are equivalent in their neutralizing effect on infectious HPV virions or pseudovirions, the binding and neutralization titers for individual MAbs were used to calculate the relative neutralization efficiency for each antibody. HPV neutralization was achieved by all MAbs capable of strong binding to either linear or conformation-sensitive epitopes on pseudovirus particles. Our data suggest, however, that some L1 epitopes may be more neutralization-sensitive than other surface epitopes, in that successful infection can be blocked by varying degrees of epitope saturation. Additionally, the effective neutralization of virions by several monovalent Fab fragments and single-chain variable fragments (scFv) demonstrates that viral neutralization does not require HPV particle aggregation or L1 crosslinking. Identification of capsid protein structures rich in neutralization-sensitive epitopes may aid in the development of improved recombinant vaccines capable of eliciting effective and long-term antibody-mediated protection against multiple HPV types.

摘要

我们比较了两组与HPV-11或HPV-16的L1表位反应的单克隆抗体(MAb)的中和能力。使用仅含L1的病毒样颗粒(VLP)和L1/L2假病毒来比较结合效价。虽然VLP在抗原性上与假病毒相似,但HPV-16颗粒在某些表位的表面暴露上存在明显差异。为了确定所有抗体结合事件对感染性HPV病毒体或假病毒体的中和作用是否等效,使用各个MAb的结合和中和效价来计算每种抗体的相对中和效率。所有能够与假病毒颗粒上的线性或构象敏感表位强烈结合的MAb都实现了HPV中和。然而,我们的数据表明,一些L1表位可能比其他表面表位对中和更敏感,因为不同程度的表位饱和都可以阻断成功感染。此外,几种单价Fab片段和单链可变片段(scFv)对病毒体的有效中和表明,病毒中和不需要HPV颗粒聚集或L1交联。鉴定富含中和敏感表位的衣壳蛋白结构可能有助于开发改进的重组疫苗,能够引发针对多种HPV类型的有效且长期的抗体介导保护。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验